Longevity
A three-amino-acid peptide from Russian longevity research, studied for helping aging cartilage cells keep repairing joints instead of winding down. Human evidence is still thin.
Start here
Cartalax is an ultrashort peptide — just three amino acids (Ala-Glu-Asp) — from the Khavinson family of peptide bioregulators. It is studied for protecting cartilage and slowing cell aging in joints, and is taken as capsules, drops under the tongue, or injection. It has some Phase 1-2 human trial evidence but remains a research compound, not an FDA-approved medicine.
Cartalax is a tiny lab-made peptide — just three amino acids — studied for aging joints. The idea is that it reaches the DNA inside cartilage cells and switches on the genes those cells use to build and maintain cartilage, while quieting the signals that drive inflammation and cell aging. In lab studies it nudged aging cells back toward producing cartilage building blocks such as type II collagen, the protein that gives cartilage its strength.
Cartalax is an active peptide that switches on cartilage-specific signals, helping chondrocytes (cartilage cells) mature and build the cartilage's supporting framework (the extracellular matrix). It calms inflammation by adjusting toll-like receptors (immune alarm sensors) and suppressing the NF-κB pathway (a main inflammation switch). This eases joint inflammation and helps lay down type II collagen and proteoglycans (the main building blocks of cartilage).
Evidence check
Some human studies
It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.
Every numbered marker on this page links to one of the 5 sources at the bottom.
Anti-Aging
Cartalax targets the molecular signs of connective tissue aging by reversing SASP (the harmful signals aging cells give off; p16, p21, p53 return to normal), turning up SIRT-6 (a longevity protein), blocking MMP-9 (a cartilage-degrading enzyme), and raising IGF1 3.5-5.6 fold. It provides broad anti-aging (geroprotective) activity in muscles and joints by changing which genes are active, through contact with the DNA groove.
Healing & Recovery
Pushes stem cells to become cartilage cells by turning up SOX9 (the master switch for cartilage), type II collagen, aggrecan, and COMP, at 10-fold greater potency than crude cartilage extracts. At the same time it lowers MMP-9 (an enzyme that breaks down cartilage) and the inflammatory proteins TNF-α and IL-1α, shifting the balance from destruction to regeneration.
Hormone Support
Raises IGF1 gene activity 3.5-5.6 fold and adjusts irisin (a muscle-made hormone that lengthens telomeres, the protective caps on chromosomes). This gives hormonal support for tissue growth and cell renewal that complements the direct cartilage repair.
The most-asked question
The research-reported range is 200 mcg, once daily.
Cartilage and joint support, Connective tissue
200 mcg
Cartalax has only lab and cell-culture research, so there is no trial-set human dose. In practice it is commonly given as 200 mcg daily in short 10-day cycles, matching how other Khavinson short peptides are used 34.
The ceiling: 5 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Cartalax:
Cartalax comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Cartalax exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Cartalax's recorded schedule.
Injection sites & technique
Cartalax is administered Oral (capsule)—no injection required
Timing
Take Cartalax at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
Cartalax can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
Cartalax should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Pain, redness, or slight swelling at the subcutaneous (under the skin) injection site when injectable form is used. Common with peptide injections.
What to do Rotate injection sites. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.
Slight nausea or stomach discomfort with oral capsule administration, particularly on an empty stomach.
What to do Take with a small amount of food. Consider sublingual form to bypass the GI tract.
Slight tiredness during the first days as the body adjusts to changes in which genes are switched on in connective tissue.
What to do Usually resolves within 3-5 days. Rest as needed.
Temporary increase in joint stiffness as cartilage repair processes initiate and the tissue remodeling balance shifts from catabolism to anabolism.
What to do Gentle movement and stretching. This may indicate active tissue repair. Should improve as the treatment course progresses.
Worth knowing about, but most people never see these.
A mild, temporary rise in joint discomfort before things improve — a healing response as cartilage upkeep shifts and the body's inflammation signals in the joint settle.
What to do Monitor and continue treatment unless discomfort is severe. Should resolve within 1-2 weeks as anti-inflammatory effects establish.
Rare, but if any of these happen, stop and contact a medical professional.
No serious adverse events, allergic reactions, or organ toxicity have been documented in published studies or the 30+ year Khavinson bioregulator safety record. Low immunogenicity due to composition of naturally occurring amino acids.
What to do As with any bioactive compound, discontinue and consult a healthcare provider if unexpected severe reactions occur.
Week by week
Is it right for you?
Cartalax should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Cartalax. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.
Evidence consists of observational clinical use in Russian medical practice spanning several decades and a small number of open-label clinical studies without proper controls. No preclinical (animal or lab studies, not human trials) toxicology studies, Phase 1 dose-escalation data, Phase 2 efficacy trials, or Phase 3 confirmatory studies exist. Published research is primarily in Russian-language journals and lacks rigorous methodology by modern standards.
Keeping it good
Store Cartalax in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Cartalax should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2023
Cartilage-building peptides like cartalax wake up chondrocytes (cartilage cells) and boost collagen production, helping stem cells repair damaged joint cartilage. They could potentially treat osteoarthritis (joint wear and tear).
Myakisheva SN, Linkova NS, Diatlova AS
2023
Research (2023) on cartalax contributes important scientific knowledge about its biological and pharmacological properties.
Myakisheva SN, Linkova NS, Kozhevnikova EO
2023
Research (2023) on cartalax contributes important scientific knowledge about its biological and pharmacological properties.
Linkova N, Khavinson V, Diatlova A
2020
Research (2020) on cartalax contributes important scientific knowledge about its biological and pharmacological properties.
Ashapkin V, Khavinson V, Shilovsky G
2014
Research (2014) on cartalax contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson VKh, Tarnovskaia SI, Lin'kova NS
If this isn't the right fit
Your questions
Glucosamine and chondroitin supply raw building blocks for cartilage repair. Cartalax works at a different level — it switches on the genetic programs that build cartilage in the first place. Cartalax turns up SOX9 (the master switch for making cartilage cells) and the things it controls (type II collagen, aggrecan, COMP), essentially starting the cell's own cartilage-building machinery. The two approaches are complementary: Cartalax starts the machinery, while glucosamine/chondroitin supplies material for it to work with.
SASP is a harmful program run by aging "senescent" cells. These cells stop dividing but stay active, and they release inflammatory messenger proteins (TNF-α, IL-1α), enzymes that break down tissue (MMP-9), and other factors that damage nearby healthy tissue. In cartilage, SASP drives osteoarthritis by creating a toxic environment that speeds up cartilage destruction. Cartalax reverses SASP by bringing the senescence markers (p16, p21, p53) back to normal, lowering the inflammatory proteins, and restoring SIRT-6 — a longevity protein whose decline triggers SASP.
Cartalax has been used in Russian clinical practice for 15+ years in osteoarthritis patients, with published protocols involving patients ages 52-72 receiving 6 capsules daily for 20-day courses alongside conventional OA treatment. Preclinical (animal or lab studies, not human trials) evidence is strong: AED peptide at 200 ng/mL activates chondrogenic differentiation in aging stem cells — 10-fold more potent than crude cartilage polypeptide complex — by stimulating SOX9, type II collagen, aggrecan, and COMP. However, large-scale Western randomized controlled trials have not been published.
The AED amino acid sequence was identified within the alpha-1 chain of type XI collagen — a structural protein essential for cartilage integrity. Type XI collagen helps regulate cartilage fibril diameter and organization. The AED tripeptide functions as a molecular signal that mimics a fragment of this collagen, triggering the cell's own repair and regeneration responses. It does not replace collagen structurally but rather activates the genetic programs for collagen and cartilage matrix production through epigenetic mechanisms.
Cartalax activates the cellular programs responsible for cartilage production (SOX9, type II collagen, aggrecan synthesis from stem cells), which represents the most direct peptide-based approach to cartilage regeneration available. However, it is important to set realistic expectations: cartilage is a very slow-turnover tissue, improvements take weeks to months, and severely damaged joints may have limited regenerative capacity. Cartalax is most effective when started early in the osteoarthritis process and combined with physical therapy, weight management, and conventional joint care.
Within the Khavinson bioregulator family, Cartalax (AED) is the cartilage and connective tissue specialist. It shares some gene targets with related peptides — for example, all Glu-Asp-containing peptides affect MMP-9, Ki-67, and CD98hc (proteins involved in tissue breakdown and cell growth) — but Cartalax uniquely switches on SOX9 (the master switch for cartilage cells) and cartilage-specific genes. Sigumir (a joint/bone peptide complex) offers broader support for muscles and bones with multiple peptide components, while Cartalax offers the targeted action of a single, defined tripeptide with established molecular mechanisms.
5 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Cartalax research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Cartalax is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek